Lung Cancer

EA5152

A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients with Previously Treated Non-Squamous NSCLC

---

EA5161

Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

---

EA5162

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

---

S1400K (NCT# pending) Requires prior entry to S1400 screening study.

A Phase II Study of ABBV-399 (Process II) in Patients with C-Met Positive Stage IV or  Recurrent Squamous Cell Lung Cancer (LUNG MAP SUB-STUDY)

---

S1400F (NCT03373760) Requires prior entry to S1400 screening study.

A Phase II Study of MED14736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)

---

A221504 (NCT03087708)

A Randomized, Double-Blind, Placebo-Controlled Pilot of Naloxegol (an Oral, Selective Peripheral Opioid Receptor Antagonist) in Advanced Non-Small Cell Lung Cancer (Adenocarcinoma)

---

NRG LU002 (NCT03137771)

Maintenance systemic therapy versus consolidative sterotactic body radiation therapy (SBRT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer: A randomized phases II/III trial.

---

NRG CC003 (NCT02635009) – Temporarily Closed

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

---

Alliance C30610 (NCT00632835)

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide

---

SWOG S1400 (NCT02154490)

A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)

---